The comparative study of the effects of miglitol and voglibose (alpha-glucosidase inhibitors) on incretins secretion

The comparative study of the effects of miglitol and voglibose (alpha-glucosidase inhibitors) on incretins secretion - The study of relationships between alpha-glucosidase inhibitors and incretins

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001671

Enrollment

Registered

2009-02-01

Start date

2008-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type-2 diabetes

Interventions

miglitol 50 mg thrice a day voglibose 0.3 mg thrice a day

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) at baseline, HbA1c 6.5%-8.0% and /or plasma glucose >= 200mg/dl 2) type-2 diabetes 3) a patient who can gave consents by him- or herself

Exclusion criteria

Exclusion criteria: 1) type-1 diabetes 2) severe hepatic or renal disease 3) severe heart disease 4) having canceres 5) unstable diabetic retinpathy 6) having a condyion to be worsened by increase in intestinal gas 7) a woman who is nursing or pregnant 8) after gstrectomy 9) a patient who is judged as not appropriate for participation

Design outcomes

Primary

Measure	Time frame
Coparisons of changes in plasma glucose, insulin, GLP-1 and GIP in response to a mixed meal before and after administration of miglitol or voglibose.	—

Secondary

Measure	Time frame
HbA1c, body weight, BMI, serum levels of adiponectin, high-sense CRP and MCP-1 at baseline and 3 month aftrer administrations of miglitol or voglibose.	—

Countries

Japan

Contacts

Public ContactTakuma Narita

Akita University School of Medicine Department of Endocrinology, Diabetes and Geriatric Medicine

narita@med.akita-u.ac.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026